Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Recommendation of “Buy” by Brokerages

Perspective Therapeutics, Inc. (NYSE:CATX) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. Ten analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $20.63.

CATX has been the topic of several analyst reports. Oppenheimer restated an “outperform” rating and set a $22.00 target price on shares of Perspective Therapeutics in a report on Friday, October 11th. UBS Group assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Wedbush reiterated an “outperform” rating and issued a $20.00 target price on shares of Perspective Therapeutics in a report on Thursday, October 24th. Finally, Truist Financial started coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target for the company.

Perspective Therapeutics Stock Down 4.5 %

CATX opened at $11.25 on Tuesday. The business’s 50 day simple moving average is $13.09. Perspective Therapeutics has a fifty-two week low of $2.20 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. On average, equities research analysts anticipate that Perspective Therapeutics will post -0.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CATX. Bleakley Financial Group LLC acquired a new position in shares of Perspective Therapeutics during the first quarter worth about $40,000. nVerses Capital LLC bought a new position in shares of Perspective Therapeutics during the 3rd quarter worth approximately $57,000. US Bancorp DE raised its holdings in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Perspective Therapeutics in the second quarter worth $117,000. Finally, Point72 DIFC Ltd acquired a new position in Perspective Therapeutics during the second quarter worth $118,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.